What we claim is:

1. A taste masking pharmaceutical composition for oral administration, comprising a core of active ingredient and one or more outer non-active taste masking layers formed on the core by application of pressure.

2. A composition according to Claim 1, in which there is a plurality of superposed non-active layers.

3. A composition according to Claim 2, wherein each layer from the layer adjacent the core, to the outermost layer is formed in turn by application of pressure.

4. A composition according to Claim 1, wherein each layer forming the outer layer, is applied by a compression method to form the outer layer.

5. A composition according to Claim 4, wherein the outer non-active layer comprises powder blends or granules which are compressed onto the core to form said outer layer.

6. A composition according to Claim 5, wherein the powder blends or granules are formed by either a wet granulation process, or a dry compaction or slugging de-slugging process, or a direct compression process.

7. A composition according to Claim 1, the outer layer encases substantially the whole surface area of the core.

8. A composition according Claim 1, wherein the outer surface of the outer layer comprises a surface profile.

9. A composition according to Claim 8, wherein the surface profile is an engraved surface profile.

10. A composition according to Claim 8, wherein the surface profile is an intaglio surface profile.

11. A composition according to Claims 8, further comprising an applied indicia.

12. A composition according to Claim 11, the applied indicia comprising a printed indicia.

13. A composition according to Claim 1 wherein the core further comprises one or more pharmaceutical excipients.

14. A composition according to Claim 1, wherein a outer non-active layer comprises one or more pharmaceutical carrier(s) and excipient(s).

15. The composition according to Claim 1, wherein an outer layer comprises a lubricating agent, a disintegrating agent, and a diluting agent.

16 A composition according to Claim 15, wherein the lubricating agent is about 0.1 to 5% magnesium stearate, the disintegrating agent is about 0.05 to 15% croscarmellose sodium, and the diluting agent is about 30 to 90% microcrystalline cellulose.

17. A composition according to Claim 1, in which the outer layer is further film coated.

18. A composition according to Claims 1, wherein the outer layer is formed by a multiple compression method.

19. A composition according to Claim 1, wherein the core comprises 0.01mg to 1000 mg of one or more active ingredients.

20. A composition according to Claim 1, wherein the core comprises more than one active ingredients.

21. A composition according to Claim 1, wherein the active ingredient or ingredients are selected from the group consisting of sumatriptan and its pharmacologically acceptable salts.

22. A composition according to claim 21, the active ingredient comprising sumatriptan succinate.

23. A taste masking pharmaceutical composition for oral administration, comprising a core of sumaptriptan and one or more outer non-active layers formed on the core by application of pressure.

24. The composition of Claim 23 wherein the sumatriptan is provided as a pharmaceutically acceptable salt.

25. The composition of Claim 24 wherein the sumatriptan is the succinate salt.

26. The composition of Claim 23 wherein the core contains about 25 to 200 mg of sumatriptan calculated as the free base.

27. The composition of Claim 23 wherein the core contains about 25 to 100 mg of sumatriptan calculated as the free base.

28. The composition of Claim 23 wherein the core comprises sumatriptan or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients selected from the group comprising binders, disintegrating agents, fillers, lubricants, wetting agents, surfactants, glidants, flavoring agents, sweetening agents, and colorants.

29. The composition of Claim 23 wherein the sumatriptan or a pharmaceutically acceptable salt thereof is granulated with a disintegrant, a filler, and a lubricant, and compressed to make the core.

30. The core of Claim 29, wherein the disintegrant is about 2.50 to 10.0 mg croscarmellose sodium, the filler is about 10 to 150 mg lactose, and the lubricant is about 0.87 to 3.50 mg magnesium stearate.

31. The composition of Claim 23 wherein the non-active layers comprise one or more pharmaceutically acceptable excipients selected from the group comprising binders, disintegrating agents, fillers, lubricants, wetting agents, surfactants, glidants, flavoring agents, sweetening agents and colorants.

32. The composition of Claim 23, wherein the non-active outer layer comprises a filler, one or more disintegrating agents, and a lubricant.

33. The outer layer of Claim 32, comprising about 160 to 300 mg lactose, about 35 to 60 mg microcrystalline cellulose, about 7.0 to 12.0 mg croscarmellose sodium, and about 2.00 to 3.50 mg magnesium stearate.

34. A method of treating migraine which comprises administering the composition of Claim 23.

35. A process for preparing taste masked pharmaceutical tablet for oral administration comprising the steps of:
forming core of active ingredient; and
applying at least one taste-masking layer of pharmaceutical excipients on the active core by compression

36. A dosage form of sumatriptan comprising inner core of sumatriptan with one or more pharmaceutically acceptable excipients and at least one outer compressed layer of pharmaceutically acceptable excipients

37. A method treating a human suffering from migraine which comprises administering the composition of Claim 36.

38. A process for preparing sumatriptan tablet for oral administration comprising the steps of:
forming core of sumatriptan or pharmaceutically acceptable salt thereof; and
applying at least one layer of pharmaceutical excipients on the core by compression.